Iniciar sesión Regístrese gratis

Suda Pharmaceuticals Ltd Propiedad de la dirección

¿Qué es el Propiedad de la dirección de Suda Pharmaceuticals Ltd?

El Propiedad de la dirección de Suda Pharmaceuticals Ltd es 13.19%

¿Cuál es la definición de Propiedad de la dirección?



La propiedad de personas con información privilegiada se calcula como el número total de acciones propiedad de personas con información privilegiada (accionistas que poseen más del 5% de la corporación o un funcionario o director de la compañía) dividido por el total de Acciones en circulación.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Propiedad de la dirección de compañías en Sector Health Care en ASX en comparadas con Suda Pharmaceuticals Ltd

¿Qué hace Suda Pharmaceuticals Ltd?

Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.

Empresas con propiedad de la dirección similar a Suda Pharmaceuticals Ltd